These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7652488)

  • 1. Tumour markers: current status and future applications.
    Aziz K
    Scand J Clin Lab Invest Suppl; 1995; 221():153-5. PubMed ID: 7652488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FDA's perspective on the evaluation of tumor marker tests.
    Aziz KJ; Maxim PE
    Clin Chem; 1993 Nov; 39(11 Pt 2):2439-43. PubMed ID: 8222256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of tumour markers.
    Schwartz MK
    Scand J Clin Lab Invest Suppl; 1995; 221():5-14. PubMed ID: 7652491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYFRA 21-1--clinical applications and analytical requirements.
    Ebert W; Bodenmüller H; Hölzel W
    Scand J Clin Lab Invest Suppl; 1995; 221():72-80. PubMed ID: 7544488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the role of established tumour markers.
    Beastall GH; Cook B; Rustin GJ; Jennings J
    Ann Clin Biochem; 1991 Jan; 28 ( Pt 1)():5-18. PubMed ID: 2024935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An expert system approach for the objective interpretation of serum tumour marker levels.
    Stajić S; Novaković R; Bosnjaković V
    Nucl Med Commun; 1994 Apr; 15(4):298-304. PubMed ID: 8072745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour marker evaluation in patients with lung cancer.
    Seregni E; Botti C; Bogni A; Bombardieri E
    Scand J Clin Lab Invest Suppl; 1995; 221():67-71. PubMed ID: 7652492
    [No Abstract]   [Full Text] [Related]  

  • 9. Forsaking cures for cancer: why are we discarding the tumour biospecimens of most patients?
    Gedye C; Fleming J
    Med J Aust; 2016 May; 204(8):297-8. PubMed ID: 27125797
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical applications of serum tumor markers.
    Bates SE
    Ann Intern Med; 1991 Oct; 115(8):623-38. PubMed ID: 1716430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
    Hayes DF; Bast RC; Desch CE; Fritsche H; Kemeny NE; Jessup JM; Locker GY; Macdonald JS; Mennel RG; Norton L; Ravdin P; Taube S; Winn RJ
    J Natl Cancer Inst; 1996 Oct; 88(20):1456-66. PubMed ID: 8841020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic sensitivity, diagnostic specificity and predictive value of the determination of tumour markers.
    Wagener C
    J Clin Chem Clin Biochem; 1984 Dec; 22(12):969-79. PubMed ID: 6527105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical application of tumour markers: a review.
    Amayo AA; Kuria JG
    East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lectin-based biosensors as analytical tools for clinical oncology.
    Silva MLS
    Cancer Lett; 2018 Nov; 436():63-74. PubMed ID: 30125611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.
    Wang HY; Hsieh CH; Wen CN; Wen YH; Chen CH; Lu JJ
    PLoS One; 2016; 11(6):e0158285. PubMed ID: 27355357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of novel tumour markers.
    Rhodes JM
    Ann Oncol; 1999; 10 Suppl 4():118-21. PubMed ID: 10436801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fantastic voyage: the future of cancer diagnostics.
    Sundaresan TK; Haber DA
    Lancet Oncol; 2015 Dec; 16(16):1596-8. PubMed ID: 26678190
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers.
    Gregory JJ; Finlay JL
    Drugs; 1999 Apr; 57(4):463-7. PubMed ID: 10235686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.